Coleman’s group has already demonstrated that this type of sequence analysis based on para-sulfonato-calix[n]arene derivatives as a protein ligand enables the identification of other types of pharmaceutical targets, such as the Tau protein, which is involved in neurodegenerative diseases [24]. Here, MAPT is linked to neurodegenerative disease.